Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays cut their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Stock Performance

NASDAQ CLLS opened at $1.91 on Thursday. Cellectis has a twelve month low of $1.70 and a twelve month high of $3.77. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a market cap of $106.16 million, a P/E ratio of -1.47 and a beta of 3.10. The company’s 50-day simple moving average is $1.99 and its 200 day simple moving average is $2.22.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. During the same period in the previous year, the firm posted ($0.31) earnings per share. As a group, research analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in Cellectis during the 2nd quarter valued at $29,000. First Affirmative Financial Network bought a new stake in shares of Cellectis during the third quarter worth $45,000. Principal Financial Group Inc. increased its stake in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares in the last quarter. Finally, Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the last quarter. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.